Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
In the TELIGAN phase 3 trial, telitacicept — a dual BAFF/APRIL inhibitor already approved for SLE — reduced 24-hour proteinuria by 55% relative to placebo at 39 weeks in adults with IgA nephropathy, with eGFR remaining stable on treatment while declining on placebo.